UPDATE: Morgan Stanley Starts Cerevel Therapeutics (CERE) at Overweight

June 18, 2021 2:23 AM EDT
Get Alerts CERE Hot Sheet
Price: $24.64 -1.6%

Rating Summary:
    5 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 11 | New: 8
Trade Now! 
Join SI Premium – FREE
(Updated - June 18, 2021 2:44 AM EDT)

Morgan Stanley analyst Matthew Harrison initiates coverage on Cerevel Therapeutics (NASDAQ: CERE) with a Overweight rating and a price target of $27.00.

The analyst comments "Cerevel brings a broad neuroscience pipeline with late-stage compound tavapadon providing base valuation support and CVL-231 providing near-term catalysts. We like the neuroscience focus, strong chemistry platform and broad early-to-mid stage pipeline."

For an analyst ratings summary and ratings history on Cerevel Therapeutics click here. For more ratings news on Cerevel Therapeutics click here.

Shares of Cerevel Therapeutics closed at $13.59 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Morgan Stanley